High-collared Shigekura, winning the prize and getting soft, what is the potential of this biopharmaceutical company?

When domestic enterprises are still worrying about homogenization and going to sea, Tianjing has taken another path
.

Despite the poor overall performance of the biopharmaceutical industry this year, Tianjing Bio is still favored by Hillhouse Capital
.

According to Hillhouse Capital’s third quarter 2021 position disclosure, Hillhouse Capital only increased its holdings of three biopharmaceutical stocks, of which Tianjing Bio is still on the list and the third largest position ($520 million)

According to public information, Tianjing Biotechnology has successfully constructed two product pipelines in the world and China through independent innovation
.

Source: Heavenly creatures

Layout of highly differentiated products, rapid advancement of global pipelines

Layout of highly differentiated products, rapid advancement of global pipelines

Tianjing Bio's global pipeline adopts a "quick proof of concept" development strategy, focusing on new or highly differentiated innovative products
.

Among them, CD47 monoclonal antibody (Lezolizumab, TJC4) and CD73 monoclonal antibody (Ulelimumab, TJD5) are both in clinical phase II in China and the United States, and their progress ranks among the top three in the world

Lezolizumab (TJC4)

Lezolizumab (TJC4)

TJC4 is a new generation of CD47 monoclonal antibody developed by Tianjing Biological.
It has strong anti-tumor activity, but has very little binding to red blood cells, which minimizes the side effects of anemia after antibody injection
.

Currently, Tianjing Biosciences is conducting clinical trials of Lezolizumab in the treatment of MDS/AML, combined with Rituxan® (rituximab) in the treatment of lymphoma, and in the United States to carry out research on the combination with Keytruda® in the treatment of solid tumors
.

In 2022, TJC4 will conduct two registered studies on lymphoma and AML/MDS

In the global CD47 target competition, Gilead’s Magrolimab has made the fastest progress, and it has entered clinical phase III.
TJC4 of TJC4 is expected to become the second CD47 drug in the world and the first domestically approved CD47 drug.
Has BIC potential
.

In September 2020, Tianjing Biotechnology and AbbVie signed a US$1.
94 billion cooperation agreement on TJC4, and two CD47 dual-antibody overseas rights of more than US$1 billion, setting a record for Chinese biopharmaceutical companies to authorize overseas transactions
.

Ulelizumab (TJD5)

Ulelizumab (TJD5)

TJD5 is a highly differentiated CD73 humanized monoclonal antibody independently developed by Tianjing Bio
.

Its unique binding epitope and structure can completely inhibit CD73.

Pranalizumab (TJM2)

Pranalizumab (TJM2)

TJM2 is a neutralizing antibody against human granulocyte macrophage colony stimulating factor (GM-CSF) independently developed by Tianjing Bio
.

TJM2 has high affinity, can specifically bind to GM-CSF, and can block the binding of GM-CSF to its receptor, thereby blocking downstream signal transduction and target cell activation

TJ-CD4B (bispecific antibody)

TJ-CD4B (bispecific antibody)

TJ-CD4B/ABL111 is an innovative bispecific antibody that simultaneously targets the tumor antigen claudin 18 splice 2 (Claudin 18.
2) and the T cell co-stimulatory molecule 4-1BB, developed in cooperation with ABL Bio from South Korea.
It is the world's first Claudin 18.
2/4-1BB double antibody
.

TJ-CD4B is undergoing phase 1 clinical trials in the United States and has also been approved for phase 1 clinical trials in China

TJ-L14B (bispecific antibody)

TJ-L14B (bispecific antibody)

TJ-L14B/ABL503 is a highly differentiated bispecific antibody based on PD-L1 developed jointly by Tianjing Bio and ABL Bio, which blocks PD-L1 signal and stimulates 4-1BB signal
.

The double antibody activates 4-1BB only when the tumor cells express PD-L1, which can significantly reduce off-target effects

In addition, TJBio also has the third-generation innovative double antibody TJ-C4GM, which combines the CD47 monoclonal antibody (TJC4) with the GM-CSF monoclonal antibody (TJM2) to create an enhanced version 2.
0 CD47 antibody
.

Tianjing Biologics has also taken the lead in deploying "super antibodies" to promote the development of new generation antibody drugs with artificial intelligence-guided targeting, mRNA delivery, membrane-permeable antibodies, and tumor internal activation
.

Layout of large varieties of international competitiveness, quick listing to seize the market

Layout of large varieties of international competitiveness, quick listing to seize the market

Tianjing Biotech’s China pipeline adopts a development strategy of "fast product launches", focusing on obtaining R&D and commercialization rights from global players in the Greater China market
.

Currently, the company has two pre-BLA products, TJ202 (Fizetuzumab, CD38 monoclonal antibody) and TJ101 (Etan growth hormone)

Fizetuzumab (TJ202)

Fizetuzumab (TJ202)

TJ202 is a differentiated CD38 antibody
.

The drug is the first product in the current R&D pipeline of Tianjing Bio to reach the endpoint of a registered clinical trial.
It is suitable for the third-line treatment of multiple myeloma and is expected to become the first commercial product of Tianjing Bio and the second in China.
Listed CD38 monoclonal antibody
.

Pursuant to the license agreement signed between Tianjing Biological and MorphoSys in November 2017, Tianjing Biological has the exclusive development and commercialization rights of Fizetuzumab in Mainland China, Taiwan, Hong Kong and Macau
.

Etan Growth Hormone (TJ101)

Etan Growth Hormone (TJ101)

Etan Growth Hormone (TJ101) is a highly differentiated long-acting recombinant human growth hormone
.
The frequency of administration of the product is once a week, patient compliance is higher, and drug safety is good
.
In February of this year, Etan Growth Hormone completed the first patient administration of a registered phase 3 clinical trial in China, and it is expected to submit a new drug marketing application in 2023
.

In November 2021, Tianjing Biotechnology and Jichuan Pharmaceutical reached a strategic cooperation of more than 2 billion yuan on Yitan growth hormone, creating a new high in the Chinese biomedical market and in the entire field
.

Conclusion

Conclusion

In terms of innovative research and development, Tianjing Bio has built four major antibody engineering platforms, including antibody cytokine platform, bispecific platform, long-acting hyFc protein platform and monoclonal antibody platform
.
In the research and development of the CD47 antibody and CD73 antibody, which are known as "the successor of PD-1", it is in the world's first echelon and has great potential
.

In terms of internationalization, Tianjing Biotechnology is undoubtedly the leader of the current domestic pharmaceutical companies
.
From the very beginning, Tianjing Biotechnology implemented a two-wheel drive pipeline strategy
.
In China, Tianjing Biotechnology has adopted a license-in strategy to apply for listing or commercial sales as quickly as possible, and rely on this to quickly obtain revenue and profits
.
In the global field, the company adopts the strategy of original research and innovative drugs, and simultaneously carries out the first and second clinical trials of the original research drugs in China and the United States, and then cooperates with world-renowned pharmaceutical companies to quickly promote the company's innovative drugs to the market and commercialize them.
Maximize the potential
.

At present, Tianjing Bio has established more than 20 innovative R&D pipelines with global competitiveness.
Dr.
Zang Jingwu, the founder and chairman of Tianjing Bio, said: Next year will be an important time point, and CD47 and CD73 antibodies will have more Many important data are released
.
Dapeng's wings are just around the corner
.